To study the local immunological effects of BCG therapy in superficial bladder cancer patients, the Authors have investigated the production of interleukin-2 in the urine. Urine specimens were collected before and halfway through the six-week BCG instillation cycle. The Authors have analysed the correlation between the presence of IL-2 in the urine and the clinical response to BCG therapy.
PaganoF., BassiP., MilaniC., MeneghiniA., MaruzziD., GaberlioA.: “A low Bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?”. J. Urol., 146: 32–5, 1991.
2.
De BoerE.C., De JongW.H., SteerenbergP.A., AardenL.A., TetterooE., De GrootE.R., Van Der MeijdenA.P.M.; VegtP.D.J., DebruyneF.M.J., RuitenbergE.J.: “Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer”. Cancer Immunol. Immunother., 34 (5): 306–312, 1992.
